What is the HCW Biologics Inc. stock price forecast?

HCW Biologics Inc. is currently trading at $1.22. View real-time AI analysis on Alpha Lenz.

What is HCW Biologics Inc. insider trading activity?

View the latest insider trading data for HCW Biologics Inc. on Alpha Lenz.

What is HCW Biologics Inc.'s P/E ratio?

HCW Biologics Inc.'s P/E ratio is -0.3.

HCW Biologics Inc.

NASDAQ · HCWB

$1.22+0.88(+262.02%)Market closed

Ask about HCW Biologics Inc.'s future dividend policy...

Alpha Chat Insight

“HCW Biologics Inc. trades at a P/E of -0.3 (undervalued) with strong ROE of 397.4%.”

Ask for details →

Company Overview

HCW Biologics Inc. operates within the biotechnology sector, focusing on developing novel immunotherapies for age-related diseases and cancer. The company harnesses proprietary platform technologies aimed at advancing the treatment of senescence-associated diseases. This includes creating biologics that target the elimination of senescent cells which play a significant role in the progression of chronic diseases. HCW Biologics is actively engaged in the discovery and development stages, with research initiatives emphasizing their potential application in oncology and regenerative medicine. Its contributions are key in paving the way for innovative therapeutic solutions, aiming to address unmet needs in healthcare and improve the quality of life for aging populations. In the financial market, HCW Biologics represents the convergence of cutting-edge biotechnology with therapeutic innovation, positioning itself as a company that seeks to have a meaningful impact in the pharmaceutical landscape.

CEODr. Hing C. Wong Ph.D.

Websitehttps://www.hcwbiologics.com

SectorHealthcare

IndustryBiotechnology

Employees36

Company Statistics

FY 2025

Profile

$2.56MMarket Cap

$54.23KRevenue

0.00Shares Out

36Employees

Margins

20.00%Gross

-6693.96%EBITDA

-20757.65%Operating

-14677.14%Pre-Tax

-14677.14%Net

Valuation

-0.32P/E

0.93P/B

47.19EV/Sales

-2.04EV/EBITDA

-0.19P/FCF

Growth (CAGR)

-79.94%Rev 3Yr

-57.90%Rev 5Yr

N/AOp Inc 3Yr

N/AOp Inc 5Yr

N/ANet Inc 3Yr

N/ANet Inc 5Yr

Returns

-29.07%ROA

397.45%ROE

-24.51%ROIC

Financial Health

$1.95MCash & Cash Equivalents

$19.80MNet Debt

786.87%Debt/Equity

N/AInterest Cov

Alpha Chat Insight

“HCW Biologics Inc. trades at a P/E of -0.3 (undervalued) with strong ROE of 397.4%.”

Ask for details →

Frequently Asked Questions

HCW Biologics Inc. (ticker: HCWB) is a company listed on NASDAQ in the Healthcare sector (Biotechnology). It has approximately 36 employees. Market cap is $3M.

The current price is $1.22 with a P/E ratio of -0.32x and P/B of 0.93x.

ROE is 397.45% and operating margin is -20757.65%. Annual revenue is $54,232.